Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NCT05603910 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Endometrial Carcinoma
Unresectable Endometrial Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab
RADIATION: Hypofractionated External Beam Radiation Therapy

Sponsor

Aaron Wolfson